Pancreatic Ductal Adenocarcinoma (PDAC) trials recruiting in Maryland

All Pancreatic Ductal Adenocarcinoma (PDAC) trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
  NCT07644559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Columbia
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06040541 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore